BlossomHill Therapeutics Closes $100M Series B
Biotechnology company BlossomHill Therapeutics has raised a $100 million Series B financing round to advance its pipeline of cancer and autoimmune treatments, the company announced Thursday....To view the full article, register now.
Already a subscriber? Click here to view full article